#Enliven Therapeutics #ELVN-001 #ENABLE Trial

Enliven Therapeutics Set to Illuminate Advances in Hematologic Oncology

Burlingame, California – August 31, 2026 – Enliven Therapeutics, Inc. (Nasdaq: ELVN), a biopharmaceutical innovator in small molecule therapeutics, has announced its participation in the Society of Hematologic Oncology (SOHO) Annual Meeting scheduled from September 9 to 12, 2026, at the George R. Brown Convention Center in Houston, Texas. The company will present new findings from the ENABLE Phase 1 clinical trial of its investigational drug ELVN-001.

The upcoming presentations will include both an oral and a poster session, highlighting significant data that builds upon earlier findings shared at the European Hematology Association (EHA) Congress earlier this year. This dual presentation reiterates Enliven’s commitment to advancing the field of hematology and offering vital insights into treatment options for chronic myeloid leukemia (CML).

Presentation Details

• - Title: ENABLE: A Phase 1 Study of ELVN-001, a Novel, Selective ATP-Competitive Inhibitor of BCRABL1, in Patients with Previously Treated CP-CML
• - Presenter: Dr. Fadi Haddad, M.D.
• - Poster Session: Wednesday, September 9, 6:55 – 7:55 PM CDT, Hall B3, Level 3, Poster Number: CML-652
• - Oral Session: Thursday, September 10, 11:47 – 11:57 AM CDT in Session V on Chronic Myeloid Leukemia

After the sessions, attendees can access the full content of the presentations via Enliven's website under the